NEJM Evidence highlights in an Editorial the results of the clinical trial with MV140 recently published in that journal. MV140 showed its safety and efficacy in a randomized, double-blind, placebo-controlled, Phase 3 trial conducted in Spain and the United Kingdom.
The reduction of recurrent urinary tract infections after treatment with MV140 (UROMUNE) represents a significant health saving according to a study published in Urologia Internationalis. The savings have been calculated taking into account the healthcare costs and medication associated with this type of infection in Spain. This study was carried out at the Urology Department of the Albacete University Hospital Complex.
The results obtained with MV140 in women with recurrent urinary tract infections (UTIs) have been published in NEJM_Evidence. This is a randomized, placebo-controlled, Phase 3 clinical trial conducted in Spain and the United Kingdom to evaluate the safety and efficacy of MV140 in this condition.
Results published in Cell Reports show that MV130 protects against respiratory viral infections by inducing Trained Immunity. This type of immunity generates memory and depends on the “training” of Innate Immune System cells. Trained immunity involves epigenetic and metabolic changes that make trained cells more effective against infections, including viral infections.
According to the results published in Frontiers in Immunology, MV130 protects against experimental infection with SARS-CoV-2 in hACE2 transgenic mice. In addition, pretreatment with MV130 is shown to enhance the immunogenicity of candidate COVID-19 vaccines directed against viral protein S, enhancing both antibody and cell-specific responses.
Allergy publishes a study showing that allergoid-mannan conjugates confer tolerogenic properties to human macrophages. These cells have been described to play a relevant role in the induction of allergen-specific tolerance in sublingual immunotherapy models, so this study may help to better understand the immunological mechanisms of allergy vaccines based on these glycoconjugates.
The results of a clinical trial with MV140 in women suffering from recurrent urinary tract infections (UTI) have been presented at the ICS21 (International Continence Society) congress, as well as at the BAUS21 (British Association of Urological Surgeon), EAU21 (European Association of Urology) and AUA21 (American Urological Association). The study (phase III) has been carried out in several centers in Spain and the United Kingdom, including 240 patients in the active group and placebo.
According to a study published in Vaccine on a population of elderly people with recurrent urinary tract infections, prophylactic treatment with MV140 or with autovaccines made from a urine sample reduces the frequency of infections and improves the patients’ quality of life. Comparatively, treatment with MV140 was superior to that obtained with autovaccines.
The first results with MV130 in COPD patients have been presented at the European Respiratory Society (ERS) congress, showing its efficacy in reducing the number and intensity of exacerbations associated with this disease. The phase 3 study has been conducted in 7 hospitals including 198 patients that were followed during 18 months.
According to a study published in PLOS One, allergic patients with respiratory symptoms to peach tree pollen through their sensitization by Pru p 9 can tolerate the consumption of this fruit even if they are sensitized by Pru p 3, the main peach fruit allergen. This study, coordinated by Dr. Miguel Blanca, has been performed with the contribution of INMUNOTEK.